Immune-Onc
is a California-based biotechnology company that researches and develops immunotherapies for the treatment of cancer and solid tumors... Read moreImmune-Onc
is a California-based biotechnology company that researches and develops immunotherapies for the treatment of cancer and solid tumors... Read more
News
Feb 28, 2025
Clinical Trials Arena
Immune-Onc: Immune-Onc doses first subject in trial of IO-108 for HCC
Jul 04, 2024
Pharamceutical Technology
Immune-Onc: IO-108 by Immune Onc Therapeutics for Solid Tumor: Likelihood of Approval
Jun 14, 2024
FinanzNachrichten
Immune-Onc: Immune-Onc Therapeutics, Inc.: Immune-Onc Therapeutics to Present Additional Positive Interim Data from IO-202 Phase 1b Expansion Cohort in Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress
May 14, 2024
FinanzNachrichten
Immune-Onc: Immune-Onc Therapeutics, Inc.: Immune-Onc Therapeutics Announces Presentation of IO-202 Phase 1b Interim Data of Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress
Feb 22, 2024
Pharamceutical Technology
Immune-Onc: Immune-Onc's antibody therapy collects second FDA orphan designation
Feb 20, 2024
Marketscreener
Immune-Onc: Immune-Onc Therapeutics, Inc. Announces Phase 1b/2 Clinical Trial Collaboration with Roche
Jan 01, 2024
StreetInsider
Press Release: Immune-Onc : Immune-Onc Therapeutics to Present Additional Positive Interim Data from IO-202 Phase 1b Expansion Cohort in Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Associatio
Jun 08, 2023
FinanzNachrichten
Immune-Onc: Immune-Onc Therapeutics, Inc.: Immune-Onc Therapeutics Presents IO-202 Phase 1 Data in Patients with Relapsed or Refractory AML and CMML at the EHA Annual Meeting 2023
Apr 14, 2023
Acrofan
Immune-Onc: Immune-Onc Therapeutics to Present Encouraging Phase 1 Data for IO-108 at AACR Annual Meeting 2023
Mar 14, 2023
Acrofan
Immune-Onc: Immune-Onc Therapeutics Announces IO-108 Phase I Clinical Trial Results Selected for Oral Presentation at AACR Annual Meeting 2023
Immune-Onc Competitors
1
2
3
4
5
6
7
8
9
10